A representation from AELAM (Spanish Association of Lymphangioleiomyomatosis) has delivered a donation of 15.000€ for the research on this disease. This collaboration will be used, among others, to develop a project to study the biology of glucocorticoids in the origin and evolution of Lymphangioleiomyomatosis (LAM).

The act of delivery took place in the Duran i Reynals Hospital and counted on the attendance of the Bellvitge Institute of Biomedical Research (IDIBELL) general director, Gabriel Capellá, and the breast cancer research group of IDIBELL and the Catalan Institute of Oncology, Miquel Àngel Pujana, who leads this research.

The research group led by Dr. Miguel Angel Pujana collaborates since 2014 with the Spanish Association of Lymphangioleiomyomatosis (AELAM) in the study of different aspects of LAM, to improve the diagnosis, management and treatment of the disease.

What is LAM?

It is a very uncommon lung tumor. It impacts mainly women of reproductive age, who see cysts appearing in the lungs that affect the respiratory tract, lymphatic and blood vessels and impair breathing. Besides, lungs are progressively damaged and it might be even possible to need a transplant.

LAM is a disease wtih no cure, thus, it is necessary to promote its research and look for answers. In this way, AELAM takes action at several levels in order to raise funds and put them into research on the disease.